Results 111 to 120 of about 492 (136)

Global pharmacovigilance analysis of dermatologic toxicity in EGFR-TKI-treated NSCLC: a cross-database real-world study. [PDF]

Front Pharmacol
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source

A real-world pharmacovigilance study of four anti-non-small cell lung cancer drugs using the WHO-VigiAccess database. [PDF]

Medicine (Baltimore)
Fang C, Wu J, Hu C, Liu Q, Ma W, Zhang L, Hua P, Ding Y, Zhong Y.   +8 more
europepmc   +1 more source

Adverse reactions of second-line tyrosine kinase inhibitors in advanced hepatocellular carcinoma treatment: a descriptive analysis from WHO-VigiAccess. [PDF]

Transl Gastroenterol Hepatol
Sui W, Duan Y, Cai Z, Xia Y, Li J, Fu J.
europepmc   +1 more source

Assessing safety trends of withdrawn medications: A data-driven pharmacovigilance approach using growth models. [PDF]

Explor Res Clin Soc Pharm
Ghubade S, Shukla S.
europepmc   +1 more source

Incidence, timing, and clinical significance of adverse immune events after gene replacement therapy: A systematic review and meta-analysis. [PDF]

Mol Ther
Maurizi N, Ammirati E, Silver E, Hong K, Bui Q, Argirò A, Olivotto I, Adler ED.   +7 more
europepmc   +1 more source

Muscle toxicity reports in FAERS: a disproportionality analysis with focus on rhabdomyolysis and cross-database assessment. [PDF]

Front Pharmacol
Zhang L, Wang Y, Wang F, Ji K, Yang L, Li J.   +5 more
europepmc   +1 more source

Adverse drug reaction profiles of histone deacetylase inhibitors. [PDF]

Sci Rep
Begum R, Parsons JL, Jones AM.
europepmc   +1 more source

Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile. [PDF]

Medicina (Kaunas)
Donadoni M, La Cava L, Bizzi E, Popescu Janu V, Meschia A, Cirigliano F, Cogliati C, Gidaro A.   +7 more
europepmc   +1 more source

Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. [PDF]

EClinicalMedicine
Wang M, Chen X, Liu Z, Li Z, Zhu Z, Liu S, Xiao S.   +6 more
europepmc   +1 more source

Safety evaluation of riociguat: insights from FAERS and VigiAccess databases, and establishment of pharmacist management framework

Shujuan Zhao, Xuejiao Hong, Haiping Wang, Haixia Cai, Chiwei Guo   +4 more
core   +1 more source